FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung Cancers

(MedPage Today) -- The FDA granted accelerated approval to the bispecific antibody zenocutuzumab (Bizengri) for NRG1 gene fusion-positive pancreatic adenocarcinoma and non-small cell lung cancer (NSCLC) on Wednesday.
The approval stipulates use...